BioCentury | Feb 1, 2020
Preclinical News

Preclinical Roundup: CureVac gets CEPI funding for 2019 coronavirus; plus blockade of CD47-SIRPA for atherosclerosis, Stanford and IBM-CDHI

CureVac gets CEPI funding for 2019 coronavirus The Coalition for Epidemic Preparedness Innovations and CureVac AG are extending a February 2019 collaboration to include a vaccine against the 2019-nCoV acute respiratory disease. The company will...
BioCentury | Dec 8, 2017
Company News

Genisphere and INSERM partner to develop neurological nanotherapies

Genisphere LLC (Hatfield, Pa.) partnered with Institut National de la Sante et de la Recherche Medicale (INSERM) to investigate the use of nanotherapeutics to treat neurological diseases. INSERM scientists will use Genisphere’s 3DNA dendrimer scaffold...
BioCentury | Dec 17, 2015
Distillery Techniques

Techniques: MRI of in vivo nanoparticle distribution to predict efficacy of nanoparticle-based cancer therapies

...nanoparticles. Next steps include testing whether MRI detection of magnetic particles predicts the efficacy of nanotherapies...
BioCentury | Dec 17, 2015
Translation in Brief

Oh, the places you'll go

Drug delivery Two Harvard labs have collaborated to track nanoparticle dynamics in tumors through in vivo imaging. In a pair of studies, the teams highlighted how the efficacy of nanomedicines could be influenced and predicted...
BioCentury | Oct 26, 2009
Company News

NanoTherapies deal

...its stake in NanoTherapies to 51% from 25%. The deal includes 6 million shares of NanoTherapies'...
...in NanoTherapies. The biotech is developing calcium phosphate nanoparticles for cancer (see BioCentury, June 8). NanoTherapies LLC...
BioCentury | Jun 8, 2009
Company News

NanoTherapies deal

...NanoTherapies. The biotech is developing calcium phosphate nanoparticles for cancer. Further terms were not disclosed. NanoTherapies LLC...
Items per page:
1 - 6 of 6
BioCentury | Feb 1, 2020
Preclinical News

Preclinical Roundup: CureVac gets CEPI funding for 2019 coronavirus; plus blockade of CD47-SIRPA for atherosclerosis, Stanford and IBM-CDHI

CureVac gets CEPI funding for 2019 coronavirus The Coalition for Epidemic Preparedness Innovations and CureVac AG are extending a February 2019 collaboration to include a vaccine against the 2019-nCoV acute respiratory disease. The company will...
BioCentury | Dec 8, 2017
Company News

Genisphere and INSERM partner to develop neurological nanotherapies

Genisphere LLC (Hatfield, Pa.) partnered with Institut National de la Sante et de la Recherche Medicale (INSERM) to investigate the use of nanotherapeutics to treat neurological diseases. INSERM scientists will use Genisphere’s 3DNA dendrimer scaffold...
BioCentury | Dec 17, 2015
Distillery Techniques

Techniques: MRI of in vivo nanoparticle distribution to predict efficacy of nanoparticle-based cancer therapies

...nanoparticles. Next steps include testing whether MRI detection of magnetic particles predicts the efficacy of nanotherapies...
BioCentury | Dec 17, 2015
Translation in Brief

Oh, the places you'll go

Drug delivery Two Harvard labs have collaborated to track nanoparticle dynamics in tumors through in vivo imaging. In a pair of studies, the teams highlighted how the efficacy of nanomedicines could be influenced and predicted...
BioCentury | Oct 26, 2009
Company News

NanoTherapies deal

...its stake in NanoTherapies to 51% from 25%. The deal includes 6 million shares of NanoTherapies'...
...in NanoTherapies. The biotech is developing calcium phosphate nanoparticles for cancer (see BioCentury, June 8). NanoTherapies LLC...
BioCentury | Jun 8, 2009
Company News

NanoTherapies deal

...NanoTherapies. The biotech is developing calcium phosphate nanoparticles for cancer. Further terms were not disclosed. NanoTherapies LLC...
Items per page:
1 - 6 of 6